Scarica l'app Stockscreener
96.99
0.96%
-0.94
Dopo l'orario di chiusura:
96.99
Precedente Chiudi:
$97.93
Aprire:
$99.3
Volume 24 ore:
201.45K
Relative Volume:
0.67
Capitalizzazione di mercato:
$1.43B
Reddito:
$1.30M
Utile/perdita netta:
$-130.19M
Rapporto P/E:
-11.56
EPS:
-8.3898
Flusso di cassa netto:
$-131.94M
1 W Prestazione:
-2.63%
1M Prestazione:
-22.39%
6M Prestazione:
+52.67%
1 anno Prestazione:
+176.60%
Intervallo 1D:
$96.07
$100.12
Intervallo di 1 settimana:
$96.07
$107.90
Portata 52W:
$28.16
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Nome
Inhibrx Biosciences Inc
Settore
Industria
Telefono
(858) 795-4220
Indirizzo
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
96.99 | 1.47B | 1.30M | -130.19M | -131.94M | -8.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2024-07-23 | Iniziato | JMP Securities | Mkt Perform |
| 2024-01-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Iniziato | SMBC Nikko | Outperform |
| 2021-09-21 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating - Yahoo Finance
Form 4 Inhibrx Biosciences Inc For: 28 September By Investing.com - Investing.com Nigeria
Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock - Investing.com
Four purchases over two days: Inhibrx Biosciences (INBX) CEO's family trust bought 10,000 shares. - Stock Titan
Inhibrx Biosciences posts updated corporate presentation highlighting INBRX-106 and ozekibart clinical progress - TradingView
A bone cancer drug met its trial goal for Inhibrx Biosciences (INBX), delaying progression versus placebo. - Stock Titan
Why (INBX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Inhibrx Biosciences stock reports stronger cancer study data - AD HOC NEWS
Inhibrx Biosciences, Inc. (INBX) stock price, news, quote and history - Yahoo Finance UK
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall? - Yahoo Finance
Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock By Investing.com - Investing.com Nigeria
Form 4 Inhibrx Biosciences Inc For: 23 September By Investing.com - Investing.com Canada
Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock - Investing.com
Inhibrx Biosciences Insider Bought Shares Worth $500,000, According to a Recent SEC Filing - marketscreener.com
At $100 a share, a director's family trust bought 5,000 shares of Inhibrx Biosciences (INBX). - Stock Titan
Inhibrx Biosciences stock gains on insider buying and trial progress - AD HOC NEWS
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
Inhibrx Biosciences stock gains institutional support as Bank of America invests - AD HOC NEWS
Inhibrx Biosciences Director Kristiina Vuori Receives Corrected Stock Option Grant - Kalkine Media
Inhibrx Biosciences Director Kimberly Manhard Revises Stock Option Grant Filing - Kalkine Media
Director at Inhibrx (NASDAQ: INBX) awarded 10,000 options - Stock Titan
Inhibrx (NASDAQ: INBX) director gets 10,000 options expiring 2036 - Stock Titan
Inhibrx (INBX) corrects director's 10,000-option grant - Stock Titan
Inhibrx (INBX) corrects 10,000-option grant to director - Stock Titan
Insider Stock Purchases: September 18, 2026 - Moomoo
Inhibrx Biosciences (NASDAQ: INBX) Director Kayyem Jon Faiz Acquires 5,000 Shares at $100 Each - Kalkine Media
Citizens reiterates Market Perform on Inhibrx Biosciences stock By Investing.com - Investing.com Canada
Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock By Investing.com - Investing.com Australia
Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock - Investing.com
Family trust of Inhibrx (INBX) director adds 5,000 shares at $100 - Stock Titan
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors? - The Motley Fool
Director’s trust sells 1,500 Inhibrx (INBX) shares - Stock Titan
Director’s trust at Inhibrx (NASDAQ: INBX) logs four 500-share stock sales - Stock Titan
How Inhibrx Biosciences Inc Com (INBX) Affects Rotational Strategy Timing - Stock Traders Daily
Inhibrx Biosciences gains FDA acceptance for oz... - Pluang
Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106 - Seeking Alpha
Founder of Inhibrx Biosciences Mark Lappe Buys 2.7% More Shares - webull.com
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock By Investing.com - Investing.com South Africa
Director trust at Inhibrx (INBX) proposes $55.9K stock sale - Stock Titan
Inhibrx Biosciences Director Kimberly Manhard Sells 1,000 Shares via Revocable Trust in September 2026 - Kalkine Media
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock - Investing.com
Director’s trust at Inhibrx Biosciences (INBX) sells 1,000 shares in two days - Stock Titan
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL) - The Globe and Mail
Inhibrx director Jon Kayyem buys $567,580 in company stock By Investing.com - Investing.com South Africa
Director-linked trust plans $57.9K INBX stock sale - Stock Titan
Inhibrx, Eikon rise after insider buying - TradingView
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy - Investing.com
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy By Investing.com - Investing.com Canada
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom (NASDAQ:INBX) - Seeking Alpha
Inhibrx (INBX) investor files notice to sell 500 shares - Stock Titan
Family trust tied to Inhibrx (INBX) director buys more stock in open market - Stock Titan
Inhibrx Biosciences Inc Azioni (INBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Inhibrx Biosciences Inc Azioni (INBX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lappe Mark | Chief Executive Officer |
Sep 28 '26 |
Buy |
100.76 |
4,500 |
453,426 |
740,548 |
| Kayyem Jon Faiz | Director |
Sep 23 '26 |
Buy |
100.00 |
5,000 |
500,000 |
434,360 |
| Kayyem Jon Faiz | Director |
Sep 16 '26 |
Buy |
100.00 |
5,000 |
500,000 |
429,360 |
| MANHARD KIMBERLY | Director |
Sep 11 '26 |
Sale |
111.78 |
500 |
55,888 |
8,500 |
| MANHARD KIMBERLY | Director |
Sep 14 '26 |
Sale |
110.26 |
500 |
55,130 |
8,000 |
| MANHARD KIMBERLY | Director |
Sep 15 '26 |
Sale |
105.05 |
500 |
52,525 |
7,500 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):